Smoking as a marker of endothelial dysfunction and risk of cardiovascular complications in patients with post-infarction cardiosclerosis and chronic obstructive pulmonary disease
Examination of cardiac patients
Published March 14, 2018
Keywords
smoking
endothelial dysfunction
chronic obstructive pulmonary disease
postinfarction cardiosclerosis
endothelial dysfunction
chronic obstructive pulmonary disease
postinfarction cardiosclerosis
How to Cite
Demochko E. A., Chentsova M. I., Minushkina L. O. Smoking as a marker of endothelial dysfunction and risk of cardiovascular complications in patients with post-infarction cardiosclerosis and chronic obstructive pulmonary disease // Kremlin Medicine Journal. 2018. VOL. № 1. С. 61-66.
Abstract
The authors have analyzed the impact of smoking on the incidence and severity of cardiovascular complications in patients with chronic obstructive pulmonary disease who had survived myocardial infarction. Smokers have lower values of the ratio of forced expiratory volume at the first second to the lung forced vital capacity (0.65 ± 0.08, p = 0.005). There was no any difference in the studied groups in lab findings including C-reactive protein, fibrinogen, ferritin, erythropoietin and natriuretic peptides. Smokers have more frequent attacks of unstable angina and stay longer in hospitals.References
1. Amato M., Frigerio B., Castelnuovo S., et al. Effects of smoking regular or light cigarettes on brachial artery flowmediated dilation. Atherosclerosis. 2013; 228: 153-160.
2. Otsuka R., Watanabe H., Hirata K. et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. J.A.M.A. 2001; 286: 436-441.
3. Nana-Sinkam S.P., Lee J.D., Sotto-Santiago S., et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am. J. Respir. Crit. Care Med. 2007; 175: 676-685.
4. Gavusoglu Y, Timuralp B, Us T, Akgün Y, Kudaiberdieva G, Gorenek B, Unalir A, Goktekin O, Ata N. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology. 2004; 55: 397-402.
5. Csordas A., Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 2013; 10: 219-230.
6. Barua R.S., Ambrose J.A. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscl. Thromb. Vasc. Biol. 2013; 33: 1460-1467.
7. Oganov R.G., Maslennikova G. Ya., Successes and failures of cardiovascular prevention. Cardiovasc. Ther. Prev. 2014; 13 (1): 4-7. In Russian.
8. William B, White. Smoking-related morbidity and mortality in the cardiovascular setting. Prev. Cardiol. 2007; 10 (2 Suppl. 1): 1–4.
9. Oganov R.G., Deev A.D., Zhukovsky G.S., et al.The effect of smoking on mortality from chronic non-communicable diseases, according to the results of a prospective study. Disease prevention and health promotion. 1998; 3: 13–15. In Russian.
10. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am. Heart. J. 1988; 115: 242–249.
11. Shalnova S.A., Deev A.D., Oganov R.G. Factors influencing cardiovascular mortality in Russian population. Cardiovasc. Ther. Prev. 2005; 1: 4-9. In Russian.
12. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514-1519.
13. Engstrom G., Lind P., Hedblad B., et al. Lung function and cardiovascular risk. Circulation. 2002; 106: 2555-2560.
14. M. Thomsen, M. Dahl, P. Lange, J. Vestbo and B.G. Nordestgaard. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease, Am. J. Resp. Crit. Care Med. 2012; 186 (10): 982-988.
15. Zadionchenko V.S, Adasheva T.V., Sandomirskaya A.P. Endothelial dysfunction and arterial hypertension: therapeutic options. R.M.J. 2002; 2: 69-72. In Russian.
16. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28: 1245-1257.
17. Sin D.D., Wu L., Man S.F.P. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest. 2005; 127 (6): 1952–1959.
18. Boudestein L.C.M., Rutten F.H., Cramer M.J. et al. The impact of concurent heart failure on prognosis in patients with chronic bstructive pulmonary disease. Eur. J. Heart. 2009; 11: 1182-1188.
19. Lainscak M., Hodoscek L.M., Diingen H.D. et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien. Klin. Wochenschr. 2009; 121(9-10): 309-313.
20. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166 (3): 333–339.
21. Laustiola K.E., Lassila R., Nurmi A.K. Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Clin. Pharmacol. Ther. 1988; 44 (4): 426–430.
22. Kotamaki M., Manninen V., Laustiola K.E. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur. J. Clin. Pharmacol. 1993; 44 (1): 13–17.
23. Laustiola K.E., Lassila R., Kaprio J., Koskenvuo M. Decreased b-adrenergic receptor density and catecholamine response in male cigarette smokers. A study of monozygotic twin pairs discordant for smoking. Circulation. 1988; 78 (Pt. 1): 1234–1240.
24. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 1992; 304: 405–412.
2. Otsuka R., Watanabe H., Hirata K. et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. J.A.M.A. 2001; 286: 436-441.
3. Nana-Sinkam S.P., Lee J.D., Sotto-Santiago S., et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am. J. Respir. Crit. Care Med. 2007; 175: 676-685.
4. Gavusoglu Y, Timuralp B, Us T, Akgün Y, Kudaiberdieva G, Gorenek B, Unalir A, Goktekin O, Ata N. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology. 2004; 55: 397-402.
5. Csordas A., Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 2013; 10: 219-230.
6. Barua R.S., Ambrose J.A. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscl. Thromb. Vasc. Biol. 2013; 33: 1460-1467.
7. Oganov R.G., Maslennikova G. Ya., Successes and failures of cardiovascular prevention. Cardiovasc. Ther. Prev. 2014; 13 (1): 4-7. In Russian.
8. William B, White. Smoking-related morbidity and mortality in the cardiovascular setting. Prev. Cardiol. 2007; 10 (2 Suppl. 1): 1–4.
9. Oganov R.G., Deev A.D., Zhukovsky G.S., et al.The effect of smoking on mortality from chronic non-communicable diseases, according to the results of a prospective study. Disease prevention and health promotion. 1998; 3: 13–15. In Russian.
10. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am. Heart. J. 1988; 115: 242–249.
11. Shalnova S.A., Deev A.D., Oganov R.G. Factors influencing cardiovascular mortality in Russian population. Cardiovasc. Ther. Prev. 2005; 1: 4-9. In Russian.
12. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514-1519.
13. Engstrom G., Lind P., Hedblad B., et al. Lung function and cardiovascular risk. Circulation. 2002; 106: 2555-2560.
14. M. Thomsen, M. Dahl, P. Lange, J. Vestbo and B.G. Nordestgaard. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease, Am. J. Resp. Crit. Care Med. 2012; 186 (10): 982-988.
15. Zadionchenko V.S, Adasheva T.V., Sandomirskaya A.P. Endothelial dysfunction and arterial hypertension: therapeutic options. R.M.J. 2002; 2: 69-72. In Russian.
16. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28: 1245-1257.
17. Sin D.D., Wu L., Man S.F.P. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest. 2005; 127 (6): 1952–1959.
18. Boudestein L.C.M., Rutten F.H., Cramer M.J. et al. The impact of concurent heart failure on prognosis in patients with chronic bstructive pulmonary disease. Eur. J. Heart. 2009; 11: 1182-1188.
19. Lainscak M., Hodoscek L.M., Diingen H.D. et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien. Klin. Wochenschr. 2009; 121(9-10): 309-313.
20. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166 (3): 333–339.
21. Laustiola K.E., Lassila R., Nurmi A.K. Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Clin. Pharmacol. Ther. 1988; 44 (4): 426–430.
22. Kotamaki M., Manninen V., Laustiola K.E. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur. J. Clin. Pharmacol. 1993; 44 (1): 13–17.
23. Laustiola K.E., Lassila R., Kaprio J., Koskenvuo M. Decreased b-adrenergic receptor density and catecholamine response in male cigarette smokers. A study of monozygotic twin pairs discordant for smoking. Circulation. 1988; 78 (Pt. 1): 1234–1240.
24. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 1992; 304: 405–412.